The enzyme in question is lysine methyltransferase 9, or KMT9, a histone-modifying protein that previous work from the same group had already implicated in prostate tumor growth and androgen receptor signaling. In the new study, published in the journal Molecular Cancer, Jon Peñarando, Eric Metzger, Roland Schüle, and colleagues demonstrate that KMT9 does far more than drive cancer cell proliferation. It actively constructs the molecular barriers that prevent the immune system from recognizing and destroying the tumor, making it a uniquely attractive target for combination approaches designed to sensitize prostate cancer to immunotherapy.

At the center of the discovery is a chemokine signaling axis that functions as a cellular summons for immunosuppressive cells. The researchers found that KMT9 regulates the expression of C-X-C motif chemokine ligands, including CXCL5, which are secreted by prostate tumor cells and bind to the C-X-C motif chemokine receptor 2, CXCR2, on the surface of circulating myeloid cells. This ligand-receptor interaction acts as a homing beacon, drawing polymorphonuclear myeloid-derived suppressor cells, or PMN-MDSCs, into the tumor. Once recruited, these cells populate the tumor immune microenvironment in large numbers, creating a dense myeloid shield around the malignant glands.

PMN-MDSCs are among the most potent enemies of antitumor immunity. They suppress cytotoxic T cell responses through multiple mechanisms, including depletion of the amino acid arginine, production of reactive oxygen species, and interference with T cell trafficking. Using genetically engineered mouse models of prostate cancer in which Pten and Trp53, two frequently altered tumor suppressor genes, are deleted in prostate epithelium, the team showed that tumors with intact KMT9 were heavily infiltrated by these suppressive myeloid cells. When the researchers ablated the Kmt9a gene specifically in the prostate, the picture changed dramatically: PMN-MDSC recruitment collapsed, and cytotoxic T cells flooded into the tumor glands, showing clear signs of activation such as granzyme B expression.

The spatial dimension of this effect proved just as important as the cellular one. Advanced single-cell spatial phenotyping revealed that in tumors with functional KMT9, cytotoxic T cells were largely excluded from the tumor epithelium, lingering instead in the surrounding stroma where they could not make contact with their targets. This immune-excluded pattern is one of the recognized hallmarks of tumors that resist checkpoint blockade, since drugs like anti-PD-1 antibodies can only reinvigorate T cells that are physically close to the cancer cells they are meant to kill. Loss of KMT9 converted this excluded architecture into an inflamed, T cell-infiltrated landscape, precisely the configuration associated with immunotherapy responsiveness.

But KMT9’s contribution to immune evasion did not end with recruitment of suppressor cells. In a second, mechanistically distinct arm of the study, the researchers found that KMT9 also arms the tumor cells themselves against T cell attack. Chromatin immunoprecipitation sequencing showed that KMT9 binds directly to the promoter of the gene encoding arginase 1, ARG1, an enzyme that catabolizes L-arginine, an amino acid essential for T cell function and proliferation. By driving ARG1 expression in prostate tumor cells, KMT9 renders them resistant to T cell-mediated cytotoxicity, effectively allowing them to survive even when killer lymphocytes do manage to engage them.

The therapeutic implications of this dual mechanism were tested in preclinical experiments. When mice carrying Kmt9a-deficient prostate tumors were treated with SB225002, a CXCR2 inhibitor, tumor growth was inhibited to a greater degree than with either intervention alone, confirming that the chemokine axis is a clinically relevant vulnerability downstream of KMT9. Similarly, combining Kmt9a loss with numidargistat, a pharmacological inhibitor of ARG1, produced enhanced suppression of tumor growth. These combination experiments suggest that even partial disruption of the KMT9 pathway could be amplified by drugs that target the individual immune-evasion mechanisms it controls.

Importantly, the team connected their mouse findings to human disease by analyzing data from the TCGA prostate adenocarcinoma cohort, which comprises 500 prostate tumor samples and 52 healthy prostate controls. The analysis showed that KMT9 expression is elevated in prostate tumors relative to normal tissue and that high KMT9 levels correlate with shorter progression-free survival, underscoring the clinical relevance of the pathway. The consistency between the murine genetic models, the human genomic data, and the pharmacological studies lends considerable weight to the conclusion that KMT9 is not an artifact of a single experimental system but a genuine driver of immune evasion in prostate cancer.

For a field searching for ways to unlock immunotherapy in prostate cancer, the study offers a compelling conceptual framework. Rather than targeting the tumor’s defenses one at a time, inhibiting KMT9 would strike at the epigenetic master switch that controls both the recruitment of immunosuppressive myeloid cells through CXCR2 ligand expression and the intrinsic resistance of tumor cells through ARG1. Ablation of KMT9α in the mouse models produced inhibition of prostate tumor growth accompanied by a massive reduction in PMN-MDSC recruitment and a significant increase in cytotoxic T cell activation and infiltration of the tumor glands, a triple effect that few single agents have achieved in this disease.

Considerable work remains before these findings reach the clinic. KMT9 inhibitors are still in early stages of development, and the safety of systemically targeting a methyltransferase with functions in normal tissue is not yet established. The study’s authors note that their findings establish KMT9 as a therapeutic target to reprogram the immunosuppressive landscape and potentially improve the clinical efficacy of current immunotherapies, a formulation that anticipates future trials combining KMT9-directed agents with checkpoint blockade. If those efforts succeed, the stubborn resistance of prostate cancer to immunotherapy, one of the most frustrating puzzles in modern oncology, may finally begin to yield, not to a smarter antibody or a stronger checkpoint inhibitor, but to an epigenetic enzyme that had been quietly building the tumor’s defenses all along.

Subject of Research: The role of the lysine methyltransferase KMT9 in shaping the immunosuppressive tumor immune microenvironment of prostate cancer

Article Title: KMT9 drives T cell exclusion and dysfunction by promoting PMN-MDSCs infiltration and ARG1 expression in prostate cancer

Article References: Peñarando, J., Willmann, D., Sum, M., Jia, Y., Berlin, C., Braun, L. M., Chen, Z., Urban, S., Jung, M., Duteil, D., Metzger, D., Gratzke, C., Zeiser, R., Greschik, H., Schüle, R., & Metzger, E. (2026). KMT9 drives T cell exclusion and dysfunction by promoting PMN-MDSCs infiltration and ARG1 expression in prostate cancer. Molecular Cancer. https://doi.org/10.1186/s12943-026-02801-8

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02801-8

Keywords: KMT9, prostate cancer, tumor immune microenvironment, PMN-MDSCs, CXCL5, CXCR2, ARG1, cytotoxic T cells, cancer immunotherapy, epigenetics, histone methyltransferase, immune evasion

The placenta is far more than a passive conduit for nutrients and oxygen. It is a highly regulated immunological interface, an organ that must tolerate a genetically distinct fetus while still defending both mother and child from infection. Resident macrophages, the immune cells that patrol placental tissue, are central to this balancing act. In their resting, anti-inflammatory M2 state, these cells promote immune tolerance, tissue remodeling, and healthy vascular development. When they shift into the pro-inflammatory M1 state, they mount antimicrobial responses but also unleash cytokines that can damage the very tissue they inhabit. A healthy pregnancy depends on keeping this polarity in check, and the new research shows that nanoplastic particles can tip the scales decisively toward inflammation.

To probe the risk, the team built a two-tier experimental strategy that combined animal and human models. In vivo, pregnant mice were exposed to polystyrene nanoplastics during gestation, allowing the researchers to examine placental toxicity in a living system where maternal circulation, fetal development, and immune signaling all interact. In parallel, the investigators developed an in vitro co-culture system pairing HTR8/SVneo cells, a widely used model of human extravillous trophoblasts, with macrophages derived from THP-1 human monocytic leukemia cells treated with phorbol ester to induce differentiation. This dual design let the researchers observe the consequences of exposure in intact placentas while dissecting the cellular mechanisms at single-cell-type resolution.

The first major finding emerged from RNA sequencing of placentas harvested from exposed mice. Transcriptomic analysis revealed significant enrichment of inflammatory response pathways, including the gene ontology term GO:0006954 and multiple associated KEGG signaling pathways. In plain terms, the exposed placentas looked inflamed at the level of their gene expression. Crucially, the researchers then confirmed that this inflammatory signature was accompanied by a measurable shift in macrophage polarization: the population of immune cells within placental tissue had moved toward the M1, pro-inflammatory phenotype, at the expense of the M2, anti-inflammatory state that normally predominates in a healthy pregnancy.

From the sequencing data, the team zeroed in on three differentially expressed genes linked to inflammation: ARG1, which encodes arginase 1, a hallmark enzyme of the M2 program; CCR5, a chemokine receptor involved in immune cell trafficking and inflammatory signaling; and IL1R2, a decoy receptor for the inflammatory cytokine interleukin-1. All three were carried forward for validation in the human cell system using RT-qPCR, a technique that quantifies gene expression with high sensitivity. In PMA-treated THP-1 macrophages exposed to the nanoparticles, ARG1 and CCR5 were consistently downregulated, while IL1R2 was upregulated. Immunohistochemistry on placental tissue corroborated the changes at the protein level.

Among the three candidate markers, only one behaved identically across every layer of evidence. ARG1 showed consistent downregulation at both the transcriptional level, detected independently by RNA sequencing and RT-qPCR, and the translational level, detected by immunohistochemistry. CCR5 and IL1R2, by contrast, did not maintain the same coherent pattern across all assays. This convergence convinced the researchers that ARG1 stands out as a robust and reliable indicator of nanoplastic-induced placental toxicity, a biomarker candidate that could prove valuable both for future mechanistic studies and, potentially, for monitoring real-world exposure effects.

The functional implications go deeper than correlation. Because arginase 1 is a defining effector molecule of the M2 program, its suppression effectively disarms the anti-inflammatory arm of placental macrophages. In the co-culture experiments, the researchers demonstrated that nanoplastic exposure suppressed the M2 anti-inflammatory phenotype while promoting the M1 pro-inflammatory phenotype, and that this polarization shift was driven by the inhibition of ARG1 expression. In other words, the particles do not simply provoke a generic inflammatory reaction; they reprogram immune cell identity by switching off a master regulator of the tolerance-promoting state. The macrophages themselves become agents of placental injury, releasing inflammatory signals in tissue that depends on calm for its function.

This mechanism helps explain how an environmental exposure could translate into developmental risk. An inflamed placenta is an inefficient placenta. Pro-inflammatory macrophage polarization has been implicated in a range of pregnancy complications, including preeclampsia, fetal growth restriction, and abnormal trophoblast invasion, and prior work by the same group linked nanoplastic exposure to ferroptosis, an iron-dependent form of cell death, in placental tissue through epigenetic mechanisms. The new findings add an immunological layer to that picture: even before cells die, the microenvironment around them is being pushed into a state that undermines nutrient exchange, vascular remodeling, and maternal-fetal immune tolerance, all of which are essential for normal fetal growth.

The study also arrives amid a rapidly expanding body of evidence that plastic particles penetrate the most protected compartments of the human body. Researchers have quantified microplastics in human placental specimens using pyrolysis gas chromatography mass spectrometry, detected them in maternal blood and umbilical vein blood, and traced their accumulation from placenta to fetal organs in animal models. Particle size matters as well: smaller nanoplastics cross biological barriers more readily than microplastics, and previous studies have shown that different particle sizes can differentially regulate pro-inflammatory macrophage polarization. What distinguishes the new work is that it moves beyond documenting the presence of these particles and identifies a specific molecular lever, ARG1, through which they exert their effect on a critical organ.

The researchers emphasize that their findings highlight a new risk factor for fetal development, one that arises from the collision between global plastic pollution and the immunological choreography of pregnancy. While the experiments were conducted in mouse models and human cell lines, the conserved biology of macrophage polarization and placental immune regulation suggests the mechanism is plausibly relevant to human pregnancies, particularly given the documented presence of plastics in human placentas. As nanoplastic contamination of air, food, and water continues to rise, the study underscores that the most vulnerable window of human development may be quietly exposed to particles capable of reprogramming the immune cells charged with protecting it. Identifying ARG1 as a consistent molecular signature of that exposure provides researchers with a concrete target for biomarkers, interventions, and, ultimately, a better understanding of how the modern material world shapes the earliest chapters of life.

Subject of Research: Effects of gestational polystyrene nanoplastic exposure on placental function and macrophage polarization

Article Title: Gestational polystyrene nanoplastic exposure impairs placental function via ARG1-associated macrophage polarization imbalance

Article References: Yujiao, C., Yifan, L., Shanshan, L., Wei, W., Meng, Z., & Yousheng, Y. (2026). Gestational polystyrene nanoplastic exposure impairs placental function via ARG1-associated macrophage polarization imbalance. Journal of Nanoparticle Research, 28(9), Article 242. https://doi.org/10.1007/s11051-026-06764-1

Image Credits: AI Generated

DOI: 10.1007/s11051-026-06764-1

Keywords: polystyrene nanoplastics, placental toxicity, macrophage polarization, ARG1, pregnancy, placenta, inflammation, fetal development, nanotoxicology, trophpoblast, HTR8/SVneo, immune tolerance